A study in the British Journal of Cancer reports that removing KDM2A, a histone demethylase, can restore antitumor immunogenicity in liver cancer. The work places an epigenetic regulator at the center of why certain liver tumors evade immune attack. The research aligns with broader efforts to connect chromatin control to immune visibility in tumors, where epigenetic states can influence antigen presentation and inflammatory signaling. By experimentally disrupting KDM2A, the authors reported a shift toward increased immunogenicity and a more favorable interaction with immune effector mechanisms. While the report is preclinical in scope based on the summary provided, it adds a potentially actionable target to the growing menu of epigenetic approaches aimed at overcoming resistance to immune-based therapies.